644 related articles for article (PubMed ID: 17935764)
1. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis.
Didier A; Malling HJ; Worm M; Horak F; Jäger S; Montagut A; André C; de Beaumont O; Melac M
J Allergy Clin Immunol; 2007 Dec; 120(6):1338-45. PubMed ID: 17935764
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis.
Wahn U; Tabar A; Kuna P; Halken S; Montagut A; de Beaumont O; Le Gall M;
J Allergy Clin Immunol; 2009 Jan; 123(1):160-166.e3. PubMed ID: 19046761
[TBL] [Abstract][Full Text] [Related]
3. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis.
Durham SR; Yang WH; Pedersen MR; Johansen N; Rak S
J Allergy Clin Immunol; 2006 Apr; 117(4):802-9. PubMed ID: 16630937
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy.
Bufe A; Eberle P; Franke-Beckmann E; Funck J; Kimmig M; Klimek L; Knecht R; Stephan V; Tholstrup B; Weisshaar C; Kaiser F
J Allergy Clin Immunol; 2009 Jan; 123(1):167-173.e7. PubMed ID: 19130937
[TBL] [Abstract][Full Text] [Related]
5. High-dose sublingual immunotherapy in children at 8-year follow-up.
Leonardi S; Spicuzza L; La Rosa M
Ann Allergy Asthma Immunol; 2009 Mar; 102(3):259-60. PubMed ID: 19354077
[No Abstract] [Full Text] [Related]
6. Efficacy and safety of 5-grass pollen sublingual immunotherapy tablets in patients with different clinical profiles of allergic rhinoconjunctivitis.
Malling HJ; Montagut A; Melac M; Patriarca G; Panzner P; Seberova E; Didier A
Clin Exp Allergy; 2009 Mar; 39(3):387-93. PubMed ID: 19134019
[TBL] [Abstract][Full Text] [Related]
7. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis.
Didier A; Worm M; Horak F; Sussman G; de Beaumont O; Le Gall M; Melac M; Malling HJ
J Allergy Clin Immunol; 2011 Sep; 128(3):559-66. PubMed ID: 21802126
[TBL] [Abstract][Full Text] [Related]
8. Allergy immunotherapy tablet: Grazax® for the treatment of grass pollen allergy.
Senna GE; Calderon M; Milani M
Expert Rev Clin Immunol; 2011 Jan; 7(1):21-7. PubMed ID: 21162646
[TBL] [Abstract][Full Text] [Related]
9. Monoid sublingual immunotherapy.
Palma-Carlos AG; Santos AS; Branco-Ferreira M; Pregal AL; Palma-Carlos ML
Eur Ann Allergy Clin Immunol; 2006 Mar; 38(3):87-9. PubMed ID: 16752693
[TBL] [Abstract][Full Text] [Related]
10. Grass allergen tablet immunotherapy relieves individual seasonal eye and nasal symptoms, including nasal blockage.
Durham SR; Riis B
Allergy; 2007 Aug; 62(8):954-7. PubMed ID: 17620075
[TBL] [Abstract][Full Text] [Related]
11. Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: the importance of allergen-specific serum IgE.
Cox LS; Casale TB; Nayak AS; Bernstein DI; Creticos PS; Ambroisine L; Melac M; Zeldin RK
J Allergy Clin Immunol; 2012 Dec; 130(6):1327-34.e1. PubMed ID: 23122534
[TBL] [Abstract][Full Text] [Related]
12. [Sublingual immunotherapy in children with grass pollen induced allergic rhinoconjunctivitis].
Wolthers OD; Høst A; Frederiksen B; Halken S
Ugeskr Laeger; 2012 Aug; 174(35):1989-92. PubMed ID: 22929576
[TBL] [Abstract][Full Text] [Related]
13. Comparative effect of pre-coseasonal and continuous grass sublingual immunotherapy in children.
Stelmach I; Kaluzińska-Parzyszek I; Jerzynska J; Stelmach P; Stelmach W; Majak P
Allergy; 2012 Mar; 67(3):312-20. PubMed ID: 22142341
[TBL] [Abstract][Full Text] [Related]
14. Sublingual immunotherapy with a standardised grass pollen extract; a double-blind placebo-controlled study.
Hordijk GJ; Antvelink JB; Luwema RA
Allergol Immunopathol (Madr); 1998; 26(5):234-40. PubMed ID: 9885731
[TBL] [Abstract][Full Text] [Related]
15. Implementation of pre-seasonal sublingual immunotherapy with a five-grass pollen tablet during optimal dosage assessment.
Horak F; Jaeger S; Worm M; Melac M; Didier A
Clin Exp Allergy; 2009 Mar; 39(3):394-400. PubMed ID: 19134018
[TBL] [Abstract][Full Text] [Related]
16. Sublingual immunotherapy: focus on tablets.
Passalacqua G; Canonica GW
Ann Allergy Asthma Immunol; 2015 Jul; 115(1):4-9. PubMed ID: 26123419
[No Abstract] [Full Text] [Related]
17. Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years.
Dahl R; Kapp A; Colombo G; de Monchy JG; Rak S; Emminger W; Riis B; Grønager PM; Durham SR
J Allergy Clin Immunol; 2008 Feb; 121(2):512-518.e2. PubMed ID: 18155284
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of high dose sublingual immunotherapy in patients with rhinoconjunctivitis.
Worm M
Eur Ann Allergy Clin Immunol; 2006 Dec; 38(10):355-60. PubMed ID: 17274520
[TBL] [Abstract][Full Text] [Related]
19. Sublingual immunotherapy.
Corrigan C
J Allergy Clin Immunol; 2007 Feb; 119(2):515; author reply 515-7. PubMed ID: 17187850
[No Abstract] [Full Text] [Related]
20. Post-treatment efficacy of discontinuous treatment with 300IR 5-grass pollen sublingual tablet in adults with grass pollen-induced allergic rhinoconjunctivitis.
Didier A; Malling HJ; Worm M; Horak F; Sussman G; Melac M; Soulié S; Zeldin RK
Clin Exp Allergy; 2013 May; 43(5):568-77. PubMed ID: 23600548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]